May 7 |
Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates
|
May 7 |
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
|
May 7 |
Y-mAbs Therapeutics GAAP EPS of -$0.15 in-line, revenue of $19.93M misses by $2.29M
|
May 7 |
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
|
May 6 |
Y-mAbs Therapeutics Q1 2024 Earnings Preview
|
Apr 26 |
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
|
Apr 25 |
Y-mAbs to Present at 2024 ASCO Annual Meeting
|
Apr 18 |
Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%
|
Mar 28 |
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
|
Mar 20 |
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
|